Compound Collection: Off-Target Agonism in a KRAS Program, an IL-1B Antagonist, and 40 More Molecules

The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >70 additional molecules that were of interest in January 2024 along with highlights from some of our favorites, including molecules targeting SOS1, NLRP3, SMARCA2, and more.

This article highlights key patents published in September 2024, covering a range of therapeutic targets and mechanisms. It includes Nurr1 and Nur77 modulators for oncology applications, STAT3 inhibitors and CRBN-based STAT3 degraders for modulating STAT3 signaling in cancer, and CDK2 molecular glue degraders for estrogen receptor-positive breast cancer resistant to CDK4/CDK6 inhibitors. Additionally, it features ERAP1 modulators for addressing autoimmune diseases, APOL1 inhibitors for APOL1-mediated kidney diseases, and novel NEK7 inhibitors targeting the NLRP3 inflammasome pathway.

The 2024 SABCS brought together over 10,000 attendees from more than 100 countries, including leading academics, researchers, patient advocates, and healthcare professionals, to showcase state-of-the-art advances in breast cancer research. In our highlights, we will cover exciting clinical trial updates from this year’s symposium, including targeted molecules addressing key pathways such as CDK4, CDK2, and PI3Kα, along with advancements in next-generation oral SERDs (selective estrogen receptor degraders).

This October roundup features key clinical updates, including FDA approvals, significant trial results for major drug candidates, the initiation of new clinical trials, and updates on halted studies.

Here’s a quick recap of the top business news from October, including major deals, acquisitions, funding rounds, and strategic partnerships. If you missed any updates, here’s your chance to catch up on the most significant developments in the industry.